Adding Provention Bio (PRVB) $4.60 to 2022 Biotech Watch List.
This is in our 'Stocks we Hope to Double' Watch List.
LIVE QUOTE
Provention Bio (PRVB) Updates.
RELATED: Revive Therapeutics (RVVTF) Enters the Danger Zone.
Provention Bio...
Provention (PRVB) Price Target $18.
Headline Says Downgrade, But That's Near 300% Higher From Here!
LIVE QUOTE
Provention Bio (NASDAQ:PRVB) PT Lowered to $18.00 (MarketBeat).
July 7th: Provention Bio (NASDAQ:PRVB - Get Rating) had its...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found in Virtually all...
Institutional Analyst Newsletter. April 14, 2022.
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict
LIVE QUOTE
What Do We Have in April's Bag of Tricks?1. Revive Therapeutics (RVVTF) Moves a...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
As we stated earlier, Revive Therapeutics (RVVTF)...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...
Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Early Bird Gets the Worm?
Here's...
Revive Therapeutics (RVVTF) Regulatory Update Archive.
April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as the rate...
Revive Therapeutics (RVVTF, RVV): Updates and News Archive.
Recent Headlines
(See FDA Filing Submission at Bottom)
LIVE QUOTE
NEWS ARCHIVE INTRO
“These medicines have a sweet spot. If the day you get diagnosed with COVID you...
Our Best Risk to Reward Idea Ever?
Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 Pack, 12 Biotech Stocks We Expect to Double" Watch List*.
If not our best ever,...
Latest article
Rick Rule Symposium – Conference Cheat Sheet
Natural Resource Investing Symposium - Presenter Guide
We've attended hundreds and hundreds of Investment Conferences (Barclay, JP Morgan, LD Micro, Piper Sandler, Roth, VRIC) since...
GeoVax (GOVX) Surges 256%, With 207 Million Shares Trading!
What an Entertaining Week!
..and it's only Thursday.
LIVE QUOTE
(MAY 18TH)
(MAY 21ST)
So Where Does That Leave us Today?
Yes, it was a pleasant surprise to see GeoVax...
Americore (AMCOF) Funding Launched. Looks Like Good Entry Point.
All Systems Go?
A recently completed Magnetometer survey sends a strong signal to investors that the company is advancing its project in a disciplined, data-driven...
